USA

Once completed, the acquisition will integrate SPR’s technology into Medtronic’s broader pain management strategy, allowing the company to offer additional options for patients and clinicians seeking alternatives to drug-based therapies.

Fujifilm Cellular Dynamics will use the expanded site to produce its iCell product portfolio, which plays a key role in new approach methods (NAMs) used in modern drug discovery and toxicity testing.

Health authorities have continued to emphasise coordinated cross-border surveillance, especially given the movement of populations between affected regions in DRC and Uganda.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

SmartIQ was developed in collaboration with leading cardiovascular centers to tackle one of the most persistent challenges in coronary imaging: balancing high-quality images with lower radiation exposure for both patients and healthcare professionals.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.